<DOC>
	<DOC>NCT00154427</DOC>
	<brief_summary>This trial is conducted in Africa, Asia, Europe, South America and the United States of America (USA). The trial is planned to investigate the safety and efficacy of NovoSevenÂ® in the management of post-operative bleeding in patients following cardiac surgery.</brief_summary>
	<brief_title>Use of Activated Recombinant Human Factor VII in Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Postoperative bleeding according to predefined criteria for critical bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>